A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Study for patients with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma using study drug pembrolizumab
Sponsor: Merck
Enrolling: Male and Female Patients
IRB Number: AAAO8259
U.S. Govt. ID: NCT02335411
Contact: Gulam Manji, MD: 646-317-6085 / gam2140@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess the safety, tolerablility, and effectiveness of pembrolizumab alone or in combination with standard treatment (cisplatin and 5-fluorouracil) for recurrent or metastatic Gastric Cancer or Gastroesophageal Junction Cancer. Participants will be in the study for approximately 24 months.
This study is closed
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Do you suffer from gastric or gastroesophageal junction cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Gulam Manji, MD
gam2140@cumc.columbia.edu
646-317-6085
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE